Cargando…

Continuing the sequence? Towards an economic evaluation of whole genome sequencing for the diagnosis of rare diseases in Scotland

Novel developments in genomic medicine may reduce the length of the diagnostic odyssey for patients with rare diseases. Health providers must thus decide whether to offer genome sequencing for the diagnosis of rare conditions in a routine clinical setting. We estimated the costs of singleton standar...

Descripción completa

Detalles Bibliográficos
Autores principales: Abbott, Michael, McKenzie, Lynda, Moran, Blanca Viridiana Guizar, Heidenreich, Sebastian, Hernández, Rodolfo, Hocking-Mennie, Lynne, Clark, Caroline, Gomes, Joana, Lampe, Anne, Baty, David, McGowan, Ruth, Miedzybrodzka, Zosia, Ryan, Mandy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530076/
https://www.ncbi.nlm.nih.gov/pubmed/34415556
http://dx.doi.org/10.1007/s12687-021-00541-4
_version_ 1784801601664319488
author Abbott, Michael
McKenzie, Lynda
Moran, Blanca Viridiana Guizar
Heidenreich, Sebastian
Hernández, Rodolfo
Hocking-Mennie, Lynne
Clark, Caroline
Gomes, Joana
Lampe, Anne
Baty, David
McGowan, Ruth
Miedzybrodzka, Zosia
Ryan, Mandy
author_facet Abbott, Michael
McKenzie, Lynda
Moran, Blanca Viridiana Guizar
Heidenreich, Sebastian
Hernández, Rodolfo
Hocking-Mennie, Lynne
Clark, Caroline
Gomes, Joana
Lampe, Anne
Baty, David
McGowan, Ruth
Miedzybrodzka, Zosia
Ryan, Mandy
author_sort Abbott, Michael
collection PubMed
description Novel developments in genomic medicine may reduce the length of the diagnostic odyssey for patients with rare diseases. Health providers must thus decide whether to offer genome sequencing for the diagnosis of rare conditions in a routine clinical setting. We estimated the costs of singleton standard genetic testing and trio-based whole genome sequencing (WGS), in the context of the Scottish Genomes Partnership (SGP) study. We also explored what users value about genomic sequencing. Insights from the costing and value assessments will inform a subsequent economic evaluation of genomic medicine in Scotland. An average cost of £1,841 per singleton was estimated for the standard genetic testing pathway, with significant variability between phenotypes. WGS cost £6625 per family trio, but this estimate reflects the use of WGS during the SGP project and large cost savings may be realised if sequencing was scaled up. Patients and families valued (i) the chance of receiving a diagnosis (and the peace of mind and closure that brings); (ii) the information provided by WGS (including implications for family planning and secondary findings); and (iii) contributions to future research. Our costings will be updated to address limitations of the current study for incorporation in budget impact modelling and cost-effectiveness analysis (cost per diagnostic yield). Our insights into the benefits of WGS will guide the development of a discrete choice experiment valuation study. This will inform a user-perspective cost–benefit analysis of genome-wide sequencing, accounting for the broader non-health outcomes. Taken together, our research will inform the long-term strategic development of NHS Scotland clinical genetics testing services, and will be of benefit to others seeking to undertake similar evaluations in different contexts. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12687-021-00541-4.
format Online
Article
Text
id pubmed-9530076
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-95300762022-10-05 Continuing the sequence? Towards an economic evaluation of whole genome sequencing for the diagnosis of rare diseases in Scotland Abbott, Michael McKenzie, Lynda Moran, Blanca Viridiana Guizar Heidenreich, Sebastian Hernández, Rodolfo Hocking-Mennie, Lynne Clark, Caroline Gomes, Joana Lampe, Anne Baty, David McGowan, Ruth Miedzybrodzka, Zosia Ryan, Mandy J Community Genet Original Article Novel developments in genomic medicine may reduce the length of the diagnostic odyssey for patients with rare diseases. Health providers must thus decide whether to offer genome sequencing for the diagnosis of rare conditions in a routine clinical setting. We estimated the costs of singleton standard genetic testing and trio-based whole genome sequencing (WGS), in the context of the Scottish Genomes Partnership (SGP) study. We also explored what users value about genomic sequencing. Insights from the costing and value assessments will inform a subsequent economic evaluation of genomic medicine in Scotland. An average cost of £1,841 per singleton was estimated for the standard genetic testing pathway, with significant variability between phenotypes. WGS cost £6625 per family trio, but this estimate reflects the use of WGS during the SGP project and large cost savings may be realised if sequencing was scaled up. Patients and families valued (i) the chance of receiving a diagnosis (and the peace of mind and closure that brings); (ii) the information provided by WGS (including implications for family planning and secondary findings); and (iii) contributions to future research. Our costings will be updated to address limitations of the current study for incorporation in budget impact modelling and cost-effectiveness analysis (cost per diagnostic yield). Our insights into the benefits of WGS will guide the development of a discrete choice experiment valuation study. This will inform a user-perspective cost–benefit analysis of genome-wide sequencing, accounting for the broader non-health outcomes. Taken together, our research will inform the long-term strategic development of NHS Scotland clinical genetics testing services, and will be of benefit to others seeking to undertake similar evaluations in different contexts. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12687-021-00541-4. Springer Berlin Heidelberg 2021-08-20 2022-10 /pmc/articles/PMC9530076/ /pubmed/34415556 http://dx.doi.org/10.1007/s12687-021-00541-4 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Abbott, Michael
McKenzie, Lynda
Moran, Blanca Viridiana Guizar
Heidenreich, Sebastian
Hernández, Rodolfo
Hocking-Mennie, Lynne
Clark, Caroline
Gomes, Joana
Lampe, Anne
Baty, David
McGowan, Ruth
Miedzybrodzka, Zosia
Ryan, Mandy
Continuing the sequence? Towards an economic evaluation of whole genome sequencing for the diagnosis of rare diseases in Scotland
title Continuing the sequence? Towards an economic evaluation of whole genome sequencing for the diagnosis of rare diseases in Scotland
title_full Continuing the sequence? Towards an economic evaluation of whole genome sequencing for the diagnosis of rare diseases in Scotland
title_fullStr Continuing the sequence? Towards an economic evaluation of whole genome sequencing for the diagnosis of rare diseases in Scotland
title_full_unstemmed Continuing the sequence? Towards an economic evaluation of whole genome sequencing for the diagnosis of rare diseases in Scotland
title_short Continuing the sequence? Towards an economic evaluation of whole genome sequencing for the diagnosis of rare diseases in Scotland
title_sort continuing the sequence? towards an economic evaluation of whole genome sequencing for the diagnosis of rare diseases in scotland
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530076/
https://www.ncbi.nlm.nih.gov/pubmed/34415556
http://dx.doi.org/10.1007/s12687-021-00541-4
work_keys_str_mv AT abbottmichael continuingthesequencetowardsaneconomicevaluationofwholegenomesequencingforthediagnosisofrarediseasesinscotland
AT mckenzielynda continuingthesequencetowardsaneconomicevaluationofwholegenomesequencingforthediagnosisofrarediseasesinscotland
AT moranblancaviridianaguizar continuingthesequencetowardsaneconomicevaluationofwholegenomesequencingforthediagnosisofrarediseasesinscotland
AT heidenreichsebastian continuingthesequencetowardsaneconomicevaluationofwholegenomesequencingforthediagnosisofrarediseasesinscotland
AT hernandezrodolfo continuingthesequencetowardsaneconomicevaluationofwholegenomesequencingforthediagnosisofrarediseasesinscotland
AT hockingmennielynne continuingthesequencetowardsaneconomicevaluationofwholegenomesequencingforthediagnosisofrarediseasesinscotland
AT clarkcaroline continuingthesequencetowardsaneconomicevaluationofwholegenomesequencingforthediagnosisofrarediseasesinscotland
AT gomesjoana continuingthesequencetowardsaneconomicevaluationofwholegenomesequencingforthediagnosisofrarediseasesinscotland
AT lampeanne continuingthesequencetowardsaneconomicevaluationofwholegenomesequencingforthediagnosisofrarediseasesinscotland
AT batydavid continuingthesequencetowardsaneconomicevaluationofwholegenomesequencingforthediagnosisofrarediseasesinscotland
AT mcgowanruth continuingthesequencetowardsaneconomicevaluationofwholegenomesequencingforthediagnosisofrarediseasesinscotland
AT miedzybrodzkazosia continuingthesequencetowardsaneconomicevaluationofwholegenomesequencingforthediagnosisofrarediseasesinscotland
AT ryanmandy continuingthesequencetowardsaneconomicevaluationofwholegenomesequencingforthediagnosisofrarediseasesinscotland